| P50 | author | Eduard Vieta | Q20090640 |
| | Xénia Gonda | Q43376064 |
| P2093 | author name string | Konstantinos N Fountoulakis | |
| | Frank Schmidt | |
| P2860 | cites work | An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. | Q51740055 |
| | Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functioning? | Q51916267 |
| | Neurocognitive impairment in bipolar patients with and without history of psychosis. | Q51966032 |
| | A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. | Q52932623 |
| | Increasing rates of placebo response over time in mania studies. | Q53038901 |
| | Molecular targets of lithium action | Q57612919 |
| | Focus on bipolar illness | Q82269911 |
| | Genetics of psychosis; insights from views across the genome | Q22252693 |
| | Haloperidol alone or in combination for acute mania | Q24245158 |
| | The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia | Q24619976 |
| | Report of three cases that received maintenance treatment with risperidone as a mood stabilizer | Q24791405 |
| | Off-label indications for atypical antipsychotics: A systematic review | Q24803302 |
| | 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. | Q34300370 |
| | Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study | Q34655996 |
| | Treatment guidelines for bipolar disorder: a critical review. | Q36093544 |
| | Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder | Q36162402 |
| | Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials | Q36466463 |
| | Aripiprazole for schizophrenia. Systematic review | Q36552955 |
| | Role of aripiprazole in treating mood disorders | Q36688973 |
| | Aripiprazole: pharmacology and evidence in bipolar disorder | Q36808054 |
| | Maintenance treatment in bipolar disorder: a focus on aripiprazole | Q36902005 |
| | Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials | Q36936379 |
| | Continuous distribution of atypical depressive symptoms between major depressive and bipolar II disorders: dose-response relationship with bipolar family history | Q36977484 |
| | The clinical-familial correlates and naturalistic outcome of panic-disorder-agoraphobia with and without lifetime bipolar II comorbidity | Q37010932 |
| | Treatment of bipolar depression: an update | Q37013938 |
| | Magnitude of effect of lithium in short-term efficacy studies of moderate to severe manic episode | Q37030962 |
| | Diagnostic guidelines for bipolar depression: a probabilistic approach | Q37058580 |
| | Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder | Q37108184 |
| | Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or "schizoaffective") psychoses | Q37159630 |
| | The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges. | Q37292350 |
| | A UK consensus on the administration of aripiprazole for the treatment of mania | Q37326130 |
| | Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo | Q38394215 |
| | Chromosome 13q13-q14 locus overlaps mood and psychotic disorders: the relevance for redefining phenotype | Q41756731 |
| | Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study | Q44159999 |
| | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 |
| | The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. | Q46133968 |
| | Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study | Q46178044 |
| | Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial | Q46681464 |
| | Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies | Q46801835 |
| | Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study | Q46886132 |
| | A seven- year follow-up of an extremely refractory bipolar I patient. | Q46896172 |
| | Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline | Q46966757 |
| | Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder | Q46975571 |
| | A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. | Q47208132 |
| | Intramuscular aripiprazole in the control of agitation | Q48468038 |
| | Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives | Q48504841 |
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | bipolar disorder | Q131755 |
| | psychosis | Q170082 |
| | meta-analysis | Q815382 |
| P304 | page(s) | 27 | |
| P577 | publication date | 2009-12-31 | |
| P1433 | published in | Annals of General Psychiatry | Q15764563 |
| P1476 | title | Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis | |
| P478 | volume | 8 | |